Gold bars to be exempt from tariffs, White House clarifies
LONDON - Vulpes Testudo Fund, closely associated with Scancell Holdings plc (AIM:SCLP) Non-Executive Director Martin Diggle, has purchased 102,236 ordinary shares at 10.85 pence per share, according to a company statement released Friday.
The transaction, which took place on Thursday, brings the combined holdings of Vulpes Life Science Fund and Vulpes Testudo Fund to 140,387,037 ordinary shares, representing 13.53% of the company.
Scancell, listed on London’s AIM market, is developing active immunotherapies for cancer treatment through its Immunobody and Moditope platforms.
The company’s lead product from its DNA Immunobody platform, iSCIB1/iSCIB1+, is currently in Phase 2 trials for melanoma. Meanwhile, Modi-1, the primary peptide immunotherapy from the Moditope platform, is undergoing Phase 2 studies across various solid tumors.
The regulatory announcement was made in accordance with market requirements for transactions by persons discharging managerial responsibilities and their closely associated parties.
The information was disclosed in a regulatory news service announcement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.